Amgen Inc.: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors

• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Amgen: PharmaVitae forecasts at a glance
• Strategic insight
  • (Untitled sub-section)
  • 2007: Key franchise hit by damaging clinical trial data - Aranesp sales decline significantly from 2006-08
  • Prolia: returning Amgen to growth

• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Product developments
• Deals and alliances
  • Technology deals

• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • (Untitled sub-section)

• Current corporate structure
  • Pharmaceuticals

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14

• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Launch/core/expiry configuration, 2008 - 14

• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Immunology & inflammation
  • Enbrel

• Oncology
  • Neulasta

• Oncology & hematology
  • Aranesp
  • Epogen

• Oncology & musculoskeletal
  • Prolia

APPENDIX

• R&D pipeline
• References
  • Datamonitor reports

• Abbreviations

TABLES

• Table: Amgen - PharmaVitae forecasts at a glance
• Table: Amgen key product developments, 2009
• Table: Amgen product deals and alliances, 2009
• Table: Amgen technology deals and alliances, 2009
• Table: Amgen M&A activity, 2009
• Table: Amgen company announcements, 2009
• Table: Amgen future product milestones, 2009 - 11
• Table: Amgen product portfolio overview ($m), 2002 - 08
• Table: Amgen product portfolio overview ($m), 2008 - 14
• Table: Amgen prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Amgen prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Amgen launch portfolio overview ($m), 2008 - 14
• Table: Amgen core portfolio overview ($m), 2008 - 14
• Table: Amgen expiry portfolio overview ($m), 2008 - 14
• Table: Amgen prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Amgen prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Amgen sales by business unit ($m), 2002 - 08
• Table: Amgen operating revenue/cost analysis ($m), 2002 - 08
• Table: Amgen operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Amgen operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Amgen operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Enbrel: overview
• Table: Enbrel: sales forecast ($m), 2008 - 14
• Table: Remicade vs. Enbrel key approvals
• Table: Remicade vs. Enbrel vs. Humira key approvals
• Table: Neulasta: overview
• Table: Neulasta: sales forecast ($m), 2008 - 14
• Table: Aranesp: overview
• Table: Aranesp (oncology): sales forecast ($m), 2008 - 14
• Table: Aranesp (hematology): sales forecast ($m), 2008 - 14
• Table: Epogen: overview
• Table: Epogen (hematology): sales forecast ($m), 2008 - 14
• Table: Epogen (oncology): sales forecast ($m), 2008 - 14
• Table: Prolia: overview
• Table: Prolia (musculoskeletal): sales forecast ($m), 2008 - 14
• Table: Prolia (oncology): sales forecast ($m), 2008 - 14
• Table: Amgen' s R&D pipeline (Phase I - registration)

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Amgen prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Amgen' s financial performance ($m), 2002 - 14
• Figure: Overview of Amgen' s strong historical sales growth
• Figure: Amgen' s switching strategy from high sales growth to controlled cost expenditure ($m), 2002 - 14
• Figure: Year-on-year growth rates by molecule type, 2008-14 (%)
• Figure: Monoclonal antibody company market share, 2008-14 (%)
• Figure: Amgen SWOT analysis
• Figure: Amgen timeline
• Figure: M&A/divestment history
• Figure: Current corporate structure
• Figure: Amgen prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Amgen key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Amgen key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Amgen prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Amgen prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Amgen launch/core/expiry configuration ($m), 2008 - 14
• Figure: Amgen prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Amgen prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Amgen operating revenue/cost analysis ($m), 2002 - 14